Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement Analysis

See more : Hangzhou Raycloud Technology Co., Ltd. (688365.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Mountain Crest Acquisition Corp. III (MCAE) Income Statement Analysis – Financial Results
Yorbeau Resources Inc. (YRBAF) Income Statement Analysis – Financial Results
APPlife Digital Solutions, Inc. (ALDS) Income Statement Analysis – Financial Results
Kafrit Industries (1993) Ltd (KAFR.TA) Income Statement Analysis – Financial Results
Burgenland Holding Aktiengesellschaft (BHD.VI) Income Statement Analysis – Financial Results

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.biohavenpharma.com

About Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Metric	2023	2022	2021	2020	2019	2017
Revenue	0.00	0.00	462.51M	0.00	0.00	0.00
Cost of Revenue	3.37M	1.39M	91.66M	72.00K	0.00	0.00
Gross Profit	-3.37M	-1.39M	370.85M	-72.00K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	80.18%	0.00%	0.00%	0.00%
Research & Development	373.28M	437.07M	181.49M	98.46M	344.67M	0.00
General & Administrative	56.90M	130.86M	37.41M	16.05M	134.45M	0.00
Selling & Marketing	5.87M	0.00	0.00	0.00	0.00	0.00
SG&A	62.77M	130.86M	37.41M	16.05M	134.45M	0.00
Other Expenses	0.00	-1.91M	1.21M	0.00	0.00	0.00
Operating Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Cost & Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Interest Income	17.73M	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	-12.71M	0.00
Depreciation & Amortization	6.91M	1.39M	1.39M	72.00K	171.86K	52.52K
EBITDA	-429.14M	-462.80M	-217.51M	-114.43M	-479.12M	0.00
EBITDA Ratio	0.00%	0.00%	-47.03%	0.00%	0.00%	0.00%
Operating Income	-436.05M	-567.93M	-218.90M	-114.51M	-479.12M	0.00
Operating Income Ratio	0.00%	0.00%	-47.33%	0.00%	0.00%	0.00%
Total Other Income/Expenses	26.50M	-1.91M	6.47M	-4.16M	-49.26M	0.00
Income Before Tax	-409.55M	-569.84M	-212.43M	-118.67M	-528.39M	0.00
Income Before Tax Ratio	0.00%	0.00%	-45.93%	0.00%	0.00%	0.00%
Income Tax Expense	-1.38M	438.00K	1.37M	-134.30K	419.00K	0.00
Net Income	-408.17M	-570.28M	-213.80M	-118.67M	-528.81M	0.00
Net Income Ratio	0.00%	0.00%	-46.23%	0.00%	0.00%	0.00%
EPS	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
EPS Diluted	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
Weighted Avg Shares Out	71.20M	44.74M	35.82M	35.82M	48.49M	0.00
Weighted Avg Shares Out (Dil)	71.20M	44.74M	35.82M	35.82M	48.49M	0.00

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

February 29, 2024prnewswire.com

Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and...

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

February 28, 2024seekingalpha.com

Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with...

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

January 25, 2024investorplace.com

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

January 25, 2024investorplace.com

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology

January 8, 2024prnewswire.com

Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Plus, rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal...

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024prnewswire.com

NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

December 1, 2023prnewswire.com

Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous system (CNS) adverse effects associated with other anti-seizure medications (ASMs),...

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

November 16, 2023zacks.com

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

November 14, 2023prnewswire.com

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242 million from completed public offering on October 5, 2023 Completed public offering of 11,761,363 Biohaven Ltd. common shares,...